<DOC>
	<DOC>NCT00823862</DOC>
	<brief_summary>To determine safety, tolerability, and preliminary efficacy of escalating doses of SD-101 alone and SD-101 plus ribavirin in subjects with chronic hepatitis C and no prior therapy.</brief_summary>
	<brief_title>Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Signed, written, informed consent Male or female subjects, 18 to 55 years of age. Subject must have chronic infection HCV, genotype 1. Serum HCVRNA concentrations 100,000 IU/mL to 10,000,000 IU/mL No prior treatment for HCV. Must be negative for hepatitis B (HBV) and human immunodeficiency virus (HIV). Must be willing to use dual method of contraception (i.e., barrier and spermicide; birth control pills and barrier) during the study. No known hypersensitivity to study medication or to drugs chemically related to the study. Prior treatment with IFNbased therapies and/or antiviral therapies. Women with ongoing pregnancy or breast feeding and male partners of women who are pregnant. Reduced kidney function. Presence of concomitant liver diseases Signs or symptoms of hepatocellular carcinoma. Thyroid disease currently poorly controlled on prescribed medications. History of hemoglobinopathy. Evidence of severe retinopathy. Other serious medical conditions, including human immunodeficiency virus, cancer (excluding nonmelanoma skin cancer), or evidence of drug or alcohol abuse. Subjects with documented or presumed coronary artery disease, pulmonary disease, or cerebrovascular disease Clinically significant acute or chronic illnesses. History of severe psychiatric disease, especially depression, characterized by a suicide attempt, hospitalization for psychiatric disease, or a period of disability as a result of psychiatric disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HCV</keyword>
	<keyword>Immunostimulatory sequence (ISS)</keyword>
	<keyword>TLR9 (toll-like receptor 9)</keyword>
	<keyword>interferon (IFN)</keyword>
	<keyword>ribavirin</keyword>
</DOC>